Chemoembolization improves survival in patients with unresectable hepatocellular carcinoma (HCC)

Josep M. Llovet, Philippe Merle, Karl Heinz Weiss, Thomas Yau, Paul J. Ross, Vincenzo Mazzaferro, Jean–Frédéric Blanc, Yuk Ting, Chia Jui Yen, Judit Kocsis, Su Pin Choo, Wattana Sukeepaisarnjaroen, René Gérolami, Jean‐François Dufour, Edward Gane, Baek‐Yeol Ryoo, Markus Peck‐Radosavljevic, Thông Dao, Winnie Yeo, Wisut Lamlertthon, Satawat Thongsawat, Michael Teufel, Heiko Krissel,

Article2004

261 Exclusion of subcapsular tumors prevents peritoneal seeding in hepatocellular carcinoma (HCC) patients treated with radiofrequency

Fernando Pons, Mattia Squarcia, R. Vilana, Margaret Sala, Luca Bianchi, M García Ayuso, Marı́a Varela, Josep M. Llovet, C. Brú, Jordi Bruix

Journal of Hepatology

Chemoembolization improves survival in patients with unresectable hepatocellular carcinoma (HCC)

Abstract

Discussion(0)

Related publications

Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival

Percutaneous treatment for unresectable hepatocellular carcinoma. Predictors of long-term survival of 274 patients in a single institution

3507 ORAL Sorafenib improves survival in a large multi-center, randomized, placebo-controlled phase III trial in patients with hepatocellular carcinoma

Phase II Studies with Refametinib or Refametinib Plus Sorafenib in Patients with Mutant RAS Hepatocellular Carcinoma (HCC)

261 Exclusion of subcapsular tumors prevents peritoneal seeding in hepatocellular carcinoma (HCC) patients treated with radiofrequency